Today, the Academy of Medical Sciences has launched a new database for early stage UK COVID-19 preclinical therapeutics research, to boost collaboration and map the preclinical discovery landscape. The British Society for Immunology is a supporter of this project.
The project asks researchers from across academia and industry to submit projects through a short online form, and will publish the results through a new open access database, available here: http://covidpipeline.acmedsci.ac.uk/
The COVID-19 pandemic and its wider implications affect everyone, in the UK and around the world. In response, the UK and global scientific community are working at pace to understand the science of this virus and how it interacts with the body.
New medicines to treat COVID-19, or directly target the SARS-CoV-2 virus, are likely to be key to the long-term control of the pandemic. We need to ensure this research effort remains collaborative and efficient.
This project will help researchers identify collaborations, share expertise, materials and methods, avoid duplicating effort, and prioritise the most promising research.
By providing an overview of the existing landscape, the Academy also hopes to enable policymakers and funding bodies to make better strategic decisions on how best to fund and support COVID-19 preclinical research.